drugset / Trial / NCT00892944

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

NCT00892944 ↗

Phase 1 Completed 6 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.

Timeline

Start
2009-04
Primary completion
—
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2516 Unknown — Oral

Indications

No indication recorded.